Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Brown TT, et al. Among authors: murphy rl. J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5. J Infect Dis. 2015. PMID: 25948863 Free PMC article. Clinical Trial.
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.
Stein JH, Komarow L, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Parker RA, Torriani FJ; ACTG 5152s Study Team. Stein JH, et al. Among authors: murphy rl. J Clin Lipidol. 2008 Dec;2(6):464-471. doi: 10.1016/j.jacl.2008.08.442. J Clin Lipidol. 2008. PMID: 19956354 Free PMC article.
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Brown TT, et al. Among authors: murphy rl. J Infect Dis. 2020 Jun 11;221(12):2083-2084. doi: 10.1093/infdis/jiaa027. J Infect Dis. 2020. PMID: 32022230 Free PMC article. No abstract available.
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL; ACTG 888 Study Team. Koletar SL, et al. Among authors: murphy rl. AIDS. 2001 Aug 17;15(12):1509-15. doi: 10.1097/00002030-200108170-00008. AIDS. 2001. PMID: 11504983 Clinical Trial.
The pavia consensus statement.
Volberding PA, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filiced G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D. Volberding PA, et al. Among authors: murphy rl. AIDS. 2003 Apr;17 Suppl 1:S170-9. doi: 10.1097/00002030-200304001-00021. AIDS. 2003. PMID: 12870544 Review. No abstract available.
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH; ACTG 5152s Study Team. Torriani FJ, et al. Among authors: murphy rl. J Am Coll Cardiol. 2008 Aug 12;52(7):569-76. doi: 10.1016/j.jacc.2008.04.049. J Am Coll Cardiol. 2008. PMID: 18687253 Free PMC article. Clinical Trial.
335 results